title: Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN.
abstract: BACKGROUND
  The influence of hepatitis C virus (HCV) treatment on the course of HCV cryoglobulinemic membranoproliferative glomerulonephritis (MPGN) is controversial.
  
  
  METHODS
  Twenty-five patients with nephrotic-range proteinuria, mixed cryoglobulinemia, MPGN proved by renal biopsy, and HCV infection were studied for their response to antiviral treatment.
  
  
  RESULTS
  After first-line treatment with prednisone, furosemide, or plasmapheresis, antiviral therapy with standard or pegylated interferon alfa and ribavirin was introduced in 18 patients. These patients were compared with 7 patients who did not receive antiviral treatment. Mean duration of antiviral treatment was 18 +/- 10 months, with a follow-up of at least 6 months after treatment withdrawal. HCV RNA clearance (sustained virological response) was achieved in 12 of 18 patients. Compared with values before antiviral therapy, a decrease in proteinuria was observed in sustained virological responders at the end of combination therapy, as well as at the end of follow-up (mean, 2.85 +/- 2.2 [SD] versus 1 +/- 1.4 and 0.4 +/- 0.8 g/d, respectively; P < 0.05). In sustained virological responders, cryoglobulin levels at the end of treatment (0.29 +/- 0.4 g/L) and end of follow-up (0.25 +/- 0.4 g/L) were decreased (P < 0.05) compared with pretreatment values (1.38 +/- 2.2 g/L). Conversely, no changes in serum cryoglobulinemia levels were observed in nonresponders or controls. Serum creatinine levels remained stable in the 18 patients with antiviral therapy, regardless of response to treatment.
  
  
  CONCLUSIONS
  Anti-HCV treatment improved HCV-associated cryoglobulinemic glomerulonephritis.
authors.affiliation: Service de Médecine Interne, Pavillon Dieulafoy, CHU Purpan, Toulouse, France. alric.l@chu-toulouse.fr
authors.forename: Laurent
authors.initials: L
authors.lastname: Alric
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Plaisier
authors.forename: Sophie
authors.initials: S
authors.lastname: Thébault
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Péron
authors.forename: Lionel
authors.initials: L
authors.lastname: Rostaing
authors.forename: Jacques
authors.initials: J
authors.lastname: Pourrat
authors.forename: Pierre
authors.initials: P
authors.lastname: Ronco
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Piette
authors.forename: Patrice
authors.initials: P
authors.lastname: Cacoub
mesh_terms: D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D003449:Cryoglobulinemia / Q000188:drug therapy / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D015432:Glomerulonephritis, Membranoproliferative / Q000188:drug therapy* / Q000209:etiology*; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D007372:Interferons; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a